Immunovant Financial Overview
Immunovant's market cap is currently $5.38B. The company's EPS TTM is $-0.73; its P/E ratio is -9.73; Immunovant is scheduled to report earnings on November 10, 2025, and the estimated EPS forecast is $-0.72. See an overview of income statement, balance sheet, and cash flow financials.
